CoChat

The molecular characterization and clinical management of multiple myeloma in the post-genome era

Open access
Zhou, Y, Barlogie, B, Shaughnessy, J D · 2009 · Leukemia
Cited by 104

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Cancer-causing mutations disrupt coordinated, precise programs of gene expression that govern cell growth and differentiation. Microarray-based gene-expression profiling (GEP) is a powerful tool to globally analyze these changes to study cancer biology and clinical behavior. Despite overwhelming genomic chaos in multiple myeloma (MM), expression patterns within tumor samples are remarkably stable and reproducible. Unique expression patterns associated with recurrent chromosomal translocations and ploidy changes defined molecular classes with differing clinical features and outcomes. Combined molecular techniques also dissected two distinct, reproducible forms of hyperdiploid disease and have molecularly defined MM with high risk for poor clinical outcome. GEP is now used to risk-stratify patients with newly diagnosed MM. Groups with high-risk features are evident in all GEP-defined MM classes, and GEP studies of serial samples showed that risk increases over time, with relapsed disease showing dramatic GEP shifts toward a signature of poor outcomes. This suggests a common mechanism of disease evolution and potentially reflects preferential expansion of therapy-resistant cells. Correlating GEP-defined disease class and risk with outcomes of therapeutic regimens reveals class–specific benefits for individual agents, as well as mechanistic insights into drug sensitivity and resistance. Here, we review modern genomics contributions to understanding MM pathogenesis, prognosis, and therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2009.160

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 134

  1. Barlogie B, Shaughnessy J, Epstein J, Sanderson R, Anaissie E, Walker R et al. Plasma cell myeloma. In: Lichtman MA, Beutler E, Kaushansky K, Kipps TJ, Seligsohn U, Prchal J (eds). Williams Hematology, 7 edn. McGraw-Hill Professional: New York, 2005, pp 1501–1533.
  2. Ribatti D, Nico B, Vacca A . Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006; 25: 4257–4266. · DOI · Paper page
  3. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511. · DOI · Paper page
  4. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74. · DOI · Paper page
  5. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185–197. · DOI · Paper page
  6. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 102: 2951–2959. · DOI · Paper page
  7. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605–1616. · DOI · Paper page
  8. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828–1837. · DOI · Paper page
  9. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169. · DOI · Paper page
  10. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al. Molecular diagnosis of Burkitt′s lymphoma. N Engl J Med 2006; 354: 2431–2442. · DOI · Paper page
  11. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256. · DOI · Paper page
  12. Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 57–70. · DOI · Paper page
  13. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG et al. The sequence of the human genome. Science (New York, NY) 2001; 291: 1304–1351. · DOI · Paper page
  14. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860–921. · DOI · Paper page
  15. Schena M, Shalon D, Davis RW, Brown PO . Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (New York, NY) 1995; 270: 467–470. · DOI · Paper page
  16. Shalon D, Smith SJ, Brown PO . A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res 1996; 6: 639–645. · DOI · Paper page
  17. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW . Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA 1996; 93: 10614–10619. · DOI · Paper page
  18. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D . Light-directed, spatially addressable parallel chemical synthesis. Science (New York, NY) 1991; 251: 767–773. · DOI · Paper page
  19. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ . High density synthetic oligonucleotide arrays. Nat Genet 1999; 21 (1 Suppl): 20–24. · DOI · Paper page
  20. Quackenbush J . Microarray analysis and tumor classification. N Engl J Med 2006; 354: 2463–2472. · DOI · Paper page
  21. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996; 14: 457–460. · DOI · Paper page
  22. De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001; 98: 771–780. · DOI · Paper page
  23. Claudio JO, Masih-Khan E, Tang H, Goncalves J, Voralia M, Li ZH et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002; 100: 2175–2186. · DOI · Paper page
  24. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745–1757. · DOI · Paper page
  25. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy Jr J . Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2003; 101: 1128–1140. · DOI · Paper page
  26. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002; 100: 1113–1122. · DOI · Paper page
  27. Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy Jr J . Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003; 102: 592–600. · DOI · Paper page
  28. Bergsagel PL, Kuehl WM . Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333–6338. · DOI · Paper page
  29. Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005; 24: 2461–2473. · DOI
  30. Jourdan M, Reme T, Goldschmidt H, Fiol G, Pantesco V, De Vos J et al. Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells. Br J Haematol 2009; 145: 45–58. · DOI · Paper page
  31. Dalton WS . The tumor microenvironment: focus on myeloma. Cancer Treat Rev 2003; 29 (Suppl 1): 11–19. · DOI
  32. Perez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nunez G, Galende J et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 2005; 19: 449–455. · DOI
  33. Mundy GR . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev 2002; 2: 584–593. · DOI · Paper page
  34. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483–2494. · DOI · Paper page
  35. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009; 113: 517–525. · DOI · Paper page
  36. Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C et al. Angiogenesis in multiple myeloma. Eur J Cancer 2006; 42: 1581–1590. · DOI · Paper page
  37. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 2004; 34: 235–239. · DOI
  38. Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005; 23: 5334–5346. · DOI · Paper page
  39. Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB, Ely SA, Osman K et al. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 2003; 122: 728–744. · DOI
  40. Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004; 103: 1799–1806. · DOI · Paper page
  41. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A et al. Induction of angiogenesis by normal and malignant plasma cells. Blood 2009; 114: 128–143. · DOI
  42. Reiland J, Sanderson RD, Waguespack M, Barker SA, Long R, Carson DD et al. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem 2004; 279: 8047–8055. · DOI
  43. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 2003; 63: 8749–8756.
  44. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007; 109: 4914–4923. · DOI
  45. Bret C, Hose D, Reme T, Sprynski AC, Mahtouk K, Schved JF et al. Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol 2009; 145: 350–368. · DOI
  46. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103: 689–694. · DOI · Paper page
  47. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106: 1021–1030. · DOI · Paper page
  48. Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy Jr J, Yaccoby S . Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol 2006; 133: 83–92. · DOI
  49. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J . Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296–303. · DOI · Paper page
  50. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM . Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 1996; 88: 674–681. · DOI · Paper page
  51. Shaughnessy Jr J, Gabrea A, Qi Y, Brents L, Zhan F, Tian E et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001; 98: 217–223. · DOI · Paper page
  52. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191–199. · DOI · Paper page
  53. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020–2028. · DOI · Paper page
  54. Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J . Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia 2006; 20: 1288–1290. · DOI
  55. Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 2005; 23: 7296–7306. · DOI · Paper page
  56. Kuehl WM, Bergsagel PL . Multiple myeloma: evolving genetic events and host interactions. Nat Rev 2002; 2: 175–187. · DOI · Paper page
  57. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101: 1520–1529. · DOI · Paper page
  58. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL . The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92: 3025–3034. · DOI · Paper page
  59. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy Jr J . A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003; 101: 2374–2376. · DOI · Paper page
  60. Dring AM, Davies FE, Fenton JA, Roddam PL, Scott K, Gonzalez D et al. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res 2004; 10: 5692–5701. · DOI
  61. Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM et al. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica 2009; 94: 78–86. · DOI
  62. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115–130. · DOI · Paper page
  63. van Stralen E, van de Wetering M, Agnelli L, Neri A, Clevers HC, Bast BJ . Identification of primary MAFB target genes in multiple myeloma. Exp Hematol 2009; 37: 78–86. · DOI
  64. Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I et al. ARK5 is transcriptionally regulated by the large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 2005; 24: 6936–6944. · DOI
  65. Tusher VG, Tibshirani R, Chu G . Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116–5121. · DOI · Paper page
  66. Tai YT, Soydan E, Song W, Fulciniti M, Kim K, Hong F et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 2009; 113: 4309–4318. · DOI
  67. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112: 1329–1337. · DOI · Paper page
  68. Lin P, Mahdavy M, Zhan F, Zhang HZ, Katz RL, Shaughnessy JD . Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol 2004; 17: 1217–1222. · doi:10.1038/modpathol.3800169
  69. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276–2284. · DOI · Paper page
  70. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006; 9: 313–325. · DOI · Paper page
  71. Bartel TB, Haessler J, Brown TL, Shaughnessy Jr JD, van Rhee F, Anaissie E et al. F18–fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009 (in press). · DOI · Paper page
  72. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100: 10954–10959. · DOI · Paper page
  73. Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy Jr JD et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol (Baltimore, Md) 2007; 21: 486–498. · DOI · Paper page
  74. Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F et al. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol 2007; 136: 565–573. · DOI
  75. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007; 67: 2982–2989. · DOI · Paper page
  76. Zhou Y, Barlogie B, Herman D, Stephens O, Tian E, Williams D et al. Integration of DNA copy number and gene expression alteration reveal novel insights into the molecular pathogenesis and prognosis of multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2008; 12: 250.
  77. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood 2003; 101: 3849–3856. · DOI
  78. Agnelli L, Bicciato S, Fabris S, Baldini L, Morabito F, Intini D et al. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. Haematologica 2007; 92: 56–65. · DOI
  79. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108: 1724–1732. · DOI · Paper page
  80. Rosinol L, Carrio A, Blade J, Queralt R, Aymerich M, Cibeira MT et al. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol 2005; 130: 729–732. · DOI · Paper page
  81. Fabris S, Ronchetti D, Agnelli L, Baldini L, Morabito F, Bicciato S et al. Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia 2007; 21: 1113–1116. · DOI
  82. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 2009; 48: 603–614. · DOI · Paper page
  83. Carew JS, Nawrocki ST, Krupnik YV, Dunner Jr K, McConkey DJ, Keating MJ et al. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 2006; 107: 222–231. · DOI
  84. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007; 21: 582–584. · DOI
  85. Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S et al. An analysis of the clinical and biological significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008; 112: 4235–4246. · DOI
  86. Cigudosa JC, Rao PH, Calasanz MJ, Odero MD, Michaeli J, Jhanwar SC et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998; 91: 3007–3010. · DOI
  87. Gutierrez NC, Garcia JL, Hernandez JM, Lumbreras E, Castellanos M, Rasillo A et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004; 104: 2661–2666. · DOI
  88. Avet-Loiseau H, Andree-Ashley LE, Moore II D, Mellerin MP, Feusner J, Bataille R et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer 1997; 19: 124–133. · DOI · Paper page
  89. Houldsworth J, Chaganti RS . Comparative genomic hybridization: an overview. Am J Pathol 1994; 145: 1253–1260.
  90. Barrett MT, Scheffer A, Ben-Dor A, Sampas N, Lipson D, Kincaid R et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci USA 2004; 101: 17765–17770. · DOI · Paper page
  91. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 1999; 23: 41–46. · DOI · Paper page
  92. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20: 207–211. · DOI · Paper page
  93. Fabris S, Todoerti K, Mosca L, Agnelli L, Intini D, Lionetti M et al. Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma. Genes Chromosomes Cancer 2007; 46: 1109–1118. · DOI
  94. Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 2007; 110: 3291–3300. · DOI · Paper page
  95. Salmon SE, Durie BG . Clinical staging and new therapeutic approaches in multiple myeloma. Recent Results Cancer Res 1978; 65: 12–20. · doi:10.1007/978-3-642-81249-1_3
  96. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420. · DOI · Paper page
  97. Bartl R . Histologic classification and staging of multiple myeloma. Hematol Oncol 1988; 6: 107–113. · DOI
  98. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546–1558. · DOI · Paper page
  99. Greipp PR, Kumar S . Plasma cell labeling index. Methods Mol Med 2005; 113: 25–35.
  100. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112: 4017–4023. · DOI · Paper page
  101. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007; 109: 3177–3188. · DOI · Paper page
  102. Zhan F, Barlogie B, Mulligan G, Shaughnessy Jr JD, Bryant B . High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood 2008; 111: 968–969. · DOI · Paper page
  103. Chng WJ, Kuehl WM, Bergsagel PL, Fonseca R . Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia 2008; 22: 459–461. · DOI
  104. Nair B, Shaughnessy Jr JD, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F et al. Gene expression profiling of plasma cells at myeloma relapse from total therapy 2 predicts subsequent survival. Blood 2009; 113: 6572–6575. · DOI
  105. Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the intergroupe francophone du myelome. J Clin Oncol 2008; 26: 4798–4805. · DOI · Paper page
  106. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2006; 107: 3669–3675. · DOI
  107. Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008; 111: 1603–1609. · DOI
  108. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006; 108: 4194–4197. · doi:10.1182/blood-2006-06-029355
  109. Gorczynski RM, Lee L, Boudakov I . Augmented Induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation 2005; 79: 1180–1183. · DOI
  110. Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol 2007; 178: 3307–3315. · DOI
  111. Andrade VC, Vettore AL, Regis Silva MR, Felix RS, Almeida MS, de Carvalho F et al. Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma. Exp Hematol 2009; 37: 446–449. · doi:10.1016/j.exphem.2008.12.003
  112. Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res 2009; 15: 1343–1352. · DOI
  113. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005; 105: 3939–3944. · DOI · Paper page
  114. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221–230. · DOI · Paper page
  115. Sabbatini P, Rowand JL, Groy A, Korenchuk S, Liu Q, Atkins C et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res 2009; 15: 3058–3067. · DOI
  116. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy J, Barlogie B et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009; 113: 4614–4626. · DOI · Paper page
  117. Marton MJ, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 1998; 4: 1293–1301. · DOI · Paper page
  118. Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (New York, NY) 1998; 281: 533–538. · DOI · Paper page
  119. Cheok MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003; 34: 85–90. · DOI · Paper page
  120. Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002; 21: 1346–1358. · DOI · Paper page
  121. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374–14379. · DOI · Paper page
  122. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380. · DOI · Paper page
  123. Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 2003; 101: 3606–3614. · DOI
  124. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004; 101: 540–545. · DOI · Paper page
  125. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A et al. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 2008; 143: 520–531. · DOI
  126. Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin Cancer Res 2005; 11: 4251–4258. · DOI
  127. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 7516–7521. · DOI · Paper page
  128. Raje N, Kumar S, Hideshima T, Ishitsuka K, Yasui H, Chhetri S et al. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. Br J Haematol 2006; 135: 52–61. · DOI
  129. Neri P, Tassone P, Shammas M, Yasui H, Schipani E, Batchu RB et al. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Leukemia 2007; 21: 2519–2526. · DOI
  130. Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, Bilban M et al. Genome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 2008; 68: 44–54. · DOI · Paper page
  131. Duus J, Bahar HI, Venkataraman G, Ozpuyan F, Izban KF, Al-Masri H et al. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma 2006; 47: 1369–1378. · DOI
  132. Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernandez S, San-Segundo L et al. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 2009; 113: 3781–3791. · DOI
  133. Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy Jr JD . Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res 2008; 14: 4821–4829. · DOI
  134. Shaughnessy Jr JD, Qu P, Edmondson P, Herman D, Zhou Y, Tian E et al. Changes in the expression of proteasome genes in tumore cells following short-term proteasome inhibitor therapy predicts survival in multiple myeloma treated with bortezomib-containing multi-agent chemotherapy. Blood (ASH Annual Meeting Abstracts) 2008; 12: 733.

Cited by

See all 104

Metadata

Authors
Zhou, Y., Barlogie, B., & Shaughnessy, J. D.
Venue
Leukemia
Published
2009-08-06
Volume
23
Issue
11
Pages
1941-1956
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2008886056
Cited by
104
References
4
FWCI
9.11
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The molecular characterization and clinical management of multiple myeloma in the post-genome era. https://app.cochat.ai/papers/10.1038/leu.2009.160
The paper
Zhou, Y., Barlogie, B., & Shaughnessy, J. D. (2009). The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia. https://doi.org/10.1038/leu.2009.160

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.